COMPARISON OF CHARACTERISTICS AND TREATMENT OUTCOMES OF TYPE 1 AND TYPE 2 MYOPIC CHOROIDAL NEOVASCULARIZATION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

PURPOSE: This study aims to compare baseline characteristics and treatment outcomes of Type 1 and Type 2 myopic choroidal neovascularization (CNV) after 1 year of antivascular endothelial growth factors therapy and identify clinical factors associated with visual outcomes, recurrence rates, and injection numbers.

METHODS: In this retrospective study, we reviewed 171 patients with active myopic CNV treated with antivascular endothelial growth factors therapy and followed for at least 1 year. CNV types were classified using optical coherence tomography. Baseline characteristics, including best-corrected visual acuity, myopic maculopathy grade, and optical coherence tomography findings, were compared.

RESULTS: Type 1 CNVs (19.3% of cases) exhibited worse baseline best-corrected visual acuity and more advanced macular degeneration than Type 2 CNVs. Both types showed significant visual improvement equivalent to 2.2 lines post-therapy, with no difference in recurrence rates or injection numbers. Multivariate analysis revealed that baseline best-corrected visual acuity, severity of myopic macular degeneration, and presence of subretinal hyperreflective exudation were significant predictors of final best-corrected visual acuity, while CNV type was not an independent predictor.

CONCLUSION: Despite more severe macular degeneration in Type 1 CNV, both types myopic CNVs benefit significantly from antivascular endothelial growth factors therapy. These findings support extending treatment to Type 1 CNVs and highlight the need for individualized management strategies.